Emory University decreased its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 12.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,758 shares of the company’s stock after selling 7,064 shares during the quarter. Zogenix makes up 2.0% of Emory University’s holdings, making the stock its 7th biggest position. Emory University’s holdings in Zogenix were worth $2,792,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of Zogenix by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 75,721 shares of the company’s stock valued at $3,756,000 after purchasing an additional 26,445 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Zogenix by 25.6% during the third quarter. Legal & General Group Plc now owns 6,948 shares of the company’s stock valued at $344,000 after purchasing an additional 1,418 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Zogenix by 18.1% during the third quarter. Vanguard Group Inc. now owns 2,070,386 shares of the company’s stock valued at $102,691,000 after purchasing an additional 318,010 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Zogenix by 20.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,956 shares of the company’s stock valued at $108,000 after purchasing an additional 496 shares during the last quarter. Finally, Fosun International Ltd purchased a new position in shares of Zogenix during the fourth quarter valued at approximately $1,615,000.

A number of equities analysts recently weighed in on ZGNX shares. Mizuho decreased their price objective on shares of Zogenix from $71.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, April 9th. Guggenheim started coverage on shares of Zogenix in a report on Friday, February 22nd. They issued a “buy” rating and a $70.00 price objective for the company. BidaskClub upgraded shares of Zogenix from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Northland Securities set a $70.00 price objective on shares of Zogenix and gave the stock a “buy” rating in a report on Tuesday, March 19th. Finally, Piper Jaffray Companies decreased their price objective on shares of Zogenix from $72.00 to $68.00 and set an “overweight” rating for the company in a report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Zogenix presently has a consensus rating of “Buy” and a consensus price target of $61.17.

Shares of ZGNX opened at $38.75 on Monday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -12.00 and a beta of 1.96. The company has a quick ratio of 9.12, a current ratio of 9.12 and a debt-to-equity ratio of 0.02. Zogenix, Inc. has a 1-year low of $33.43 and a 1-year high of $62.75.

Zogenix (NASDAQ:ZGNX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.02. Sell-side analysts expect that Zogenix, Inc. will post -3.62 earnings per share for the current year.

In other Zogenix news, Director Renee P. Tannenbaum sold 17,503 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $50.65, for a total transaction of $886,526.95. Following the completion of the sale, the director now directly owns 19,375 shares in the company, valued at approximately $981,343.75. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Cam L. Garner sold 5,625 shares of the business’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $50.00, for a total transaction of $281,250.00. Following the sale, the director now owns 4,756 shares of the company’s stock, valued at $237,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,078 shares of company stock valued at $6,248,177. Company insiders own 4.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zogenix, Inc. (ZGNX) Shares Sold by Emory University” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2019/05/27/zogenix-inc-zgnx-shares-sold-by-emory-university.html.

Zogenix Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Recommended Story: What is the price-to-earnings growth (PEG) ratio?

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.